2-amino-5,6-dimethylindan | 162752-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-amino-5,6-dimethylindan
• 英文别名: 5,6-dimethyl-2,3-dihydro-1H-inden-2-amine
• CAS: 162752-07-0
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: OOZUFBLXOYQAGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-amino-5,6-dimethylindan 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 以194.83 g的产率得到
  参考文献：
  名称：

  一种2-氨基茚满衍生物的合成方法及其产品

  摘要：

  本发明提供了一种2‑氨基茚满衍生物的合成方法，即以5,6二取代1‑茚酮为起始原料，先进行溴化反应，再进行盖布瑞尔反应，接着加入水合肼，进行水解反应同时生成腙，最后在高沸点溶剂中加入强碱进行加热水解，制得目标产物2‑氨基茚满衍生物。本发明还提供了由上述合成方法制得的2‑氨基茚满衍生物。与现有技术中的2‑氨基茚满衍生物合成方法相比，本发明所提供的合成方法反应原料廉价，反应条件温和，反应步骤简单，易于操作，并且所得产品的收率较高，适于工业化生产，因此，具有很好的应用前景与市场潜力。

  公开号：

  CN105884626B
• 作为产物：
  描述：

  5,6-dimethyl-2-oximino-1-indanone 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 19.0~22.0 ℃ 、400.01 kPa 条件下， 反应 48.0h， 以16%的产率得到2-amino-5,6-dimethylindan
  参考文献：
  名称：

  The Identification of Indacaterol as an Ultralong-Acting Inhaled β₂-Adrenoceptor Agonist

  摘要：

  Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and evaluated for their potential as inhaled ultralong-acting bronchodilators. Determination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference beta(2)-adrenoceptor agonists. Further assessment with an in vitro superfused electrically stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compounds. From these studies the 5,6-diethylindan analogue indacaterol 1c was shown to possess a unique profile of combining a rapid onset of action with a long duration of action. Further in vivo profiling of 1c supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compound being selected as a development candidate.

  DOI：

  10.1021/jm100068m

文献信息

• [EN] CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZÈNESULFONAMIDES CYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009080223A1

  公开（公告）日：2009-07-02

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the Formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARγ激动剂活性。所描述的是Formula (I)的化合物，其中基团如所定义，并且它们的生理上可接受的盐及其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。
• Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
  申请人：SCHOENAFINGER Karl

  公开号：US20110224263A1

  公开（公告）日：2011-09-15

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，表现出PPARdelta或PPARdelta和PPARgamma激动剂活性。所描述的是式I的化合物，其中基团的定义如上所述，以及它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病，以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• Binge behavior regulators
  申请人：Golan Ezekiel

  公开号：US10137096B2

  公开（公告）日：2018-11-27

  Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

  本发明公开了利用说明书中描述和定义的式 I 所代表的 2-氨基茚满衍生物来调节酗酒行为，特别是酗酒的方法和组合物。
• Alcoholic beverage substitutes
  申请人：Clearmind Medicine Inc.

  公开号：US11528924B2

  公开（公告）日：2022-12-20

  Alcoholic beverage-substitutes such as a beer-substitute, a wine-substitute, a cider-substitute, an alcopop-substitute or a spirit-substitute beverage, comprising a base liquid (e.g., a base beverage) and a 2-aminoindan derivative such as defined by Formula I in the specification are disclosed.

  本发明公开了酒精饮料代用品，如啤酒代用品、葡萄酒代用品、苹果酒代用品、酒精饮料代用品或烈性酒代用品，包括基础液体（如基础饮料）和2-氨基茚满衍生物（如说明书中式I所定义）。
• 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS
  申请人：THE UPJOHN COMPANY

  公开号：EP0712387A1

  公开（公告）日：1996-05-22